GH Research PLC (NASDAQ:GHRS) Short Interest Up 11.3% in October

GH Research PLC (NASDAQ:GHRS) saw a large growth in short interest during the month of October. As of October 15th, there was short interest totalling 1,780,000 shares, a growth of 11.3% from the September 30th total of 1,600,000 shares. Approximately 5.9% of the shares of the stock are sold short. Based on an average trading volume of 44,300 shares, the short-interest ratio is presently 40.2 days.

GH Research Stock Down 2.8 %

Shares of GH Research stock traded down $0.23 during midday trading on Thursday, hitting $8.10. The company’s stock had a trading volume of 87,107 shares, compared to its average volume of 79,818. GH Research has a 1-year low of $5.05 and a 1-year high of $14.99. The firm has a market capitalization of $421.43 million, a P/E ratio of -12.09 and a beta of 0.79. The stock has a 50-day simple moving average of $8.09 and a 200-day simple moving average of $10.55.

GH Research (NASDAQ:GHRS) last announced its quarterly earnings data on Tuesday, September 3rd. The company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.03. As a group, sell-side analysts predict that GH Research will post -0.89 earnings per share for the current year.

Analysts Set New Price Targets

GHRS has been the subject of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of GH Research in a research report on Thursday, September 5th. JMP Securities reiterated a “market outperform” rating and issued a $39.00 target price on shares of GH Research in a report on Wednesday, September 4th.

Institutional Trading of GH Research

A hedge fund recently raised its stake in GH Research stock. Lynx1 Capital Management LP boosted its position in shares of GH Research PLC (NASDAQ:GHRS) by 19.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,966,726 shares of the company’s stock after purchasing an additional 656,163 shares during the period. GH Research accounts for approximately 16.7% of Lynx1 Capital Management LP’s portfolio, making the stock its 3rd biggest position. Lynx1 Capital Management LP owned about 7.62% of GH Research worth $46,252,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 56.90% of the company’s stock.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).